July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Real-World Use of Intravitreal Aflibercept Injections in Diabetic Macular Edema: 1-Year Interim Results of APOLLON.
Author Affiliations & Notes
  • Jean-Francois Korobelnik
    CHU de Bordeaux, Université de Bordeaux, INSERM, Bordeaux Population Health Research Center, LEHA team, Bordeaux, France
  • Laurent Kodjikian
    Centre Hospitalier de la Croix Rousse, Université de Lyon, Lyon, France
  • Vincent Daien
    Hôpital Gui De Chauliac, Montpellier, INSERM, Université de Montpellier, France
  • Celine Faure
    Clinique Saint-Martin, Ramsay Générale de Santé, Caen, France
  • Ramin Tadayoni
    Hôpital Lariboisière, AP-HP, Université Paris 7 – Sorbonne Paris Cité, Paris Hôpital, Paris, France
  • Audrey Giocanti-Aurégan
    Avicenne, AP-HP, Université Paris 13, DHU Vision et Handicaps, Bobigny, France
  • Pascale Massin
    CUDC, Hôpital Lariboisière, Paris, France
  • Footnotes
    Commercial Relationships   Jean-Francois Korobelnik, Alcon (C), Alimera (C), Allergan (C), Bayer (C), Novartis (C), Roche (C), Thea (C), Zeiss (C); Laurent Kodjikian, Alcon (F), Alcon (C), Alcon (R), Alimera (C), Alimera (R), Allergan (F), Allergan (C), Allergan (R), Bayer (F), Bayer (C), Bayer (R), Horus (R), Novartis (F), Novartis (C), Novartis (R), Roche (C), Thea Pharmaceuticals (F), Thea Pharmaceuticals (R); Vincent Daien, Bayer (C), Horus (C), Novartis (C), Thea Pharmaceuticals (C); Celine Faure, Alcon (F), Bayer (F), Novartis (F); Ramin Tadayoni, Alcon (C), Alimera (C), Allergan (C), Bausch + Lomb (C), Bayer (C), FCI (C), Genentech (C), Novartis (C), Roche (C), Thea Pharmaceuticals (C), Thrombogenics (C), Zeiss (C); Audrey Giocanti-Aurégan, Alimera (C), Allergan (C), Bayer (C), Novartis (C); Pascale Massin, Allergan (C), Bayer (C), Novartis (C), Sanofi (C), Thea Pharmaceuticals (C)
  • Footnotes
    Support  Bayer HealthCare SAS
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3651. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jean-Francois Korobelnik, Laurent Kodjikian, Vincent Daien, Celine Faure, Ramin Tadayoni, Audrey Giocanti-Aurégan, Pascale Massin; Real-World Use of Intravitreal Aflibercept Injections in Diabetic Macular Edema: 1-Year Interim Results of APOLLON.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3651.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To assess visual and anatomic outcomes in patients with diabetic macular edema (DME) treated with intravitreal aflibercept injection (IAI) in clinical practice in France.

Methods : APOLLON (NCT02924311) is an ongoing, prospective, observational, 2-year study to monitor visual (primary), anatomic, and safety outcomes following IAI in treatment-naïve or previously treated patients with DME. Previous treatment was defined as any other treatment including anti-VEGF (other than IAI), laser, or steroids. Primary endpoint was the mean change in best-corrected visual acuity (BCVA) from baseline to 12 months. Interim results at 12 months are presented here.

Results : A total of 147 patients had both baseline and 12-month data available; of these, 77 were treatment-naïve and 70 were previously treated. Of those previously treated, 44 had prior treatment with ranibizumab and 41 photocoagulation laser. Baseline demographics were largely similar between groups. Patients who were treatment-naïve had a higher BCVA score at baseline. At 12 months, change in BCVA from baseline to 12 months was +6.5 Early Treatment Diabetic Retinopathy letters (total population), +7.8 letters (treatment-naïve), and +5.0 letters (previously treated). Gains of ≥10 and ≥15 letters, respectively, were achieved in 38% and 24% of patients in the total population, 46% and 30% in the treatment-naïve group, and 32% and 19% in the previously treated group. The mean number of injections was 7.6 in the overall population as well as in both subgroups based on prior treatment. The proportion of patients who received 5 initial IAIs within the first 5 months was 51.9% in the treatment-naïve group and 31.4% in the previously treated group. Mean change in CRT from baseline to 12 months was –130 µm (total population), –121 µm (treatment-naïve), and –141 µm (previously treated). No new safety signals were observed. Ocular adverse events (AEs) were reported in 54.1% of patients. The most common ocular AEs were cataract (4.4%) and diabetic retinal edema (3.1%).

Conclusions : This 12-month interim analysis of the APOLLON study showed that IAI was associated with functional and anatomical improvements in both treatment-naïve and previously treated patients with DME in routine clinical practice in France.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.